Cravioto MC

Idioma: Español
Referencias bibliográficas: 19
Paginas: 196-198
Archivo PDF: 61.22 Kb.

FRAGMENTO

Lupus eritematoso generalizado

El lupus eritematoso generalizado (LEG) es una enfermedad autoinmune que afecta principalmente a mujeres en edad reproductiva. Sin embargo, en la mayor parte de las cohortes que existen a nivel internacional alrededor del 25-50% de las mujeres registradas se encuentran en la peri- o postmenopausia. Dentro del grupo de mujeres postmenopáusicas existe una proporción importante que presentaron la menopausia en forma prematura, debido a la actividad de la enfermedad y/o a la administración de ciclofosfamida. De acuerdo con nuestra casuística y la de otros grupos, existe además un grupo de pacientes que a lo largo de la enfermedad tienen períodos frecuentes y/o prolongados de amenorrea con normo- o hipoestrogenismo. Las principales causas de esta alteración son la administración de glucocorticoides, las alteraciones del estado general de salud, hiperprolactinemia, insuficiencia renal, etc. En todos estos casos la administración de estrógenos puede proporcionar beneficios para la salud y calidad de vida.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Cravioto MC, Romero-Díaz J, Mendoza-Fuentes A, Mestanza-Peralta M, Sánchez-Guerrero J. Menopause in systemic lupus erythematosus (SLE). Age at presentation and clinical characteristics. Menopause 1998; 5: 276.

2. Cravioto MC, Escudero Licona I, Mendoza-Fuentes A, Romero-Díaz J, Sánchez-Guerrero J. Prevalence of persistent amenorrhea and premature ovarian failure in systemic lupus erythematosus (SLE). Int J Gynaecol Obstet 2000; 70: 14.

3. Beral V, Banks E, Reeves G. Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942-4.

4. Mok CC, Lau CS, Wong RW. Use of exogenous estrogens in systemic lupus erythematosus. Semin Arthritis Rheum 2001; 30: 426-35.

5. Arden NK, Lloyd ME, Spector TD, Hughes GR. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 1994; 3: 11-3.

6. Kreidstein S, Urowitz MB, Gladman DD, Gough J. Hormone replacement therapy in systemic lupus erythematosus. J Rheumatol 1997; 24: 2149-52.

7. Mok CC, Lau CS, Ho CT, Lee KW, Mok MY, Wong RW. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol 1998; 27: 342-6.

8. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med 2005; 142: 953-62.

9. Sánchez-Guerrero J, González-Pérez M, Durand-Carbajal M, Lara-Reyes P, Bahena-Amezcua S, Cravioto MC. Effect of hormone replacement therapy (HRT) on disease activity in postmenopausal patients with SLE. A two year follow-up clinical trial. Arthritis Rheum 2001; 44: S263.

10. Sánchez-Guerrero J, Villegas A, Mendoza-Fuentes A, Romero-Díaz J, Moreno-Coutiño G, Cravioto MC. Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus. American Journal of Medicine 2001; 111: 464-8.

11. Cravioto MC, Durand-Carbajal M, Jiménez-Santana ML, Hernández-Hernández IY, Lara P, Sánchez-Guerrero J. Effect of hormone replacement therapy (HRT) on vasomotor symptoms and depression in women with systemic lupus erythematosus (SLE). A two-year follow-up clinical trial. Menopause 2002; 9: 501.

12. Ramsey-Goldman R, Dunn JE, Huan CF, Dunlop D, Rairie JE, Fitzgerald S, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United Status population data. Arthritis Rheum 1999; 42: 882-90.

13. Jasqui S, Sánchez-Guerrero J, González-Pérez M, Uribe-Lima A, García-Moreno C, Lara-Reyes P, Durand-Carbajal M, Jiménez-Santana ML, Correa-Rotter R, Cravioto MC. Effect of two year treatment with hormone replacement therapy (HRT) on bone mineral density (BMD) in postmenopausal women with systemic lupus erythematosus (SLE). Bone 2003; 32: S210.

14. Bertnatsky S, Boivin JF, Joseph L, Rajan R, Soma A, Manzi S, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1481-90.

15. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.

16. Van den Brink HR, van Everdingen AA, van Wijk MJ, Jacobs JW, Bijlsma JW. Adjuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis. Ann Rheum Dis 1993; 52: 862-5.

17. Hall GM, Daniels M, Huskisson EC, Spector TD. A randomized controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 1994; 53: 112-6.

18. Mac Donald AG, Murphy EA, Capell HA, Bankowska UZ, Ralston SH. Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo controlled study. Ann Rheum Dis 1994; 53: 54-7.

19. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37: 1499-505.